knowing 10-K coming, new CEO coming within next 1-2 weeks !!
which got completed last week. Nothing more is found. This give green light for 10-K, which I think will come by next week. New CEO news will also come next week IMO. Ackman finally driving results now.
This will propel stock to over $45 short term. After that earnings will move the stock. Earnings also has been reduced so much, its easy for them to beat.
wow if you have money in AVXL you should really read up on it. 2-73 is a combination of Sigma 1 and M1 receptor. All these 4 drugs above were some form of M1 receptor.
Am not saying 2-73 is not going to work. But this is called doing your DUE DILIGENCE.
Now you know why no BP is interested in a drug with Sigma1 + M1 receptor.
Sigma1 on its own does not work...we already know that from Tacoma trials.
Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease. It made it to phase III clinical trials before being discontinued due to poor results.
Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist. It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.
Xanomeline (LY-246,708; Lumeron, Memcor) is a muscarinic acetylcholine receptor agonist with reasonable selectivity for the M1 and M4 subtypes, though it is also known to act as a M5 receptor antagonist. It has been studied for the treatment of both Alzheimer's disease and schizophrenia, particularly the cognitive and negative symptoms, although gastrointestinal side effects led to a high drop-out rate in clinical trials.
and AF is NOT WRONG. He is stating the facts.
next 1-2 days. Those who bought over $6 want to get out !!
You are just crazy. I told you orphan means NOTHING for a preclinical. People here were so pumped up Friday like AVXL just got a FDA approval. Geesh !
Stop talking about multi billion valuations for AVXL...THEY ARE NOT EVEN DOING PLACEBO or double blinded !!! No partner cares !!
its is PRECLINICAL ! They have no funding to even take it to phase I safety profile. They have no plan anyways, they already said they want to take Rett to phase I.
Nice pop, but will cool down on Monday. This is non-event.
if they do, WHERE IS THE $ coming from ? Oprhan means nothing. Hope longs have sold today.
btw, 26 weeks is 6 months, and full enrollment finished in Sept. GET YOUR FACTS RIGHT !!! WOW !!! NOV WAS THE PRESENTATION. 6 MONTHS FROM SEPT IS MARCH. 26 weeks is over, but I seriously doubt you will get any data btw.
wow what a bunch of blind folks. Dr does not give 12 week data, even though he says he would. So what. lets start dreaming about 26 week data. What ? He doesn't give it in May conference ? so what, lets start a thread about buyout at $2 billion and stock at $50 ? That will start tonight ?
even the pos AXON has 30% institutional holding !! Check it out at nasdaqdotcom.
3.8% after stellar week 5 data is really not good. Of course, retail always knows what others don't right ?
Sept - full enrollment complete
early Nov - 5 week results
early Jan - PK/PD data for 5 weeks
12 wk should have been completed by Dec.
so by March Dr. should have his 12 wk data...but he does not want to same situation as Nov, so he wants to present this ALONG with the pk/pd, so there is no doubt and no ammo for the bashers.
Hence the delay.
Based on this calculation, early April is when he will release both wk12, pk/pd, and also partial wk24.